Literature DB >> 10487847

Vascular smooth muscle cell proliferation and regrowth after mechanical injury in vitro are Egr-1/NGFI-A-dependent.

F S Santiago1, D G Atkins, L M Khachigian.   

Abstract

Smooth muscle cell (SMC) proliferation is a key event in renarrowing of blood vessels after balloon angioplasty. Mechanical injury imparted to the arterial wall in experimental models induces the expression of the immediate-early gene, egr-1. Egr-1 binds to and activates expression from the proximal promoters of multiple genes whose products can, in turn, influence the vascular response to injury. Here, we used antisense strategies in vitro to inhibit rat vascular SMC proliferation by directly targeting Egr-1. A series of phosphorothioate antisense oligonucleotides of 15 base length and complementary to various theoretically accessible regions within Egr-1 mRNA were synthesized and assessed for their ability to selectively inhibit SMC proliferation in an Egr-1-dependent manner. Western blot analysis revealed that two oligonucleotides, AS2 and E11, inhibited Egr-1 synthesis in cells exposed to serum without affecting levels of the zinc finger protein Sp1. AS2 and E11 inhibited serum-inducible [(3)H]thymidine incorporation into DNA, as well as serum stimulation of total cell numbers. Size-matched phosphorothioate oligonucleotides with random, scrambled, sense or mismatch sequences failed to inhibit. Antisense Egr-1 inhibition was nontoxic and reversible. These oligonucleotides also inhibited SMC regrowth after mechanical injury in vitro. Egr-1 thus plays a key regulatory role in SMC proliferation and repair following injury.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10487847      PMCID: PMC1866910          DOI: 10.1016/S0002-9440(10)65189-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

Review 1.  Pharmacology of smooth muscle cell replication.

Authors:  C L Jackson; S M Schwartz
Journal:  Hypertension       Date:  1992-12       Impact factor: 10.190

2.  Inducible PDGF A-chain transcription in smooth muscle cells is mediated by Egr-1 displacement of Sp1 and Sp3.

Authors:  E S Silverman; L M Khachigian; V Lindner; A J Williams; T Collins
Journal:  Am J Physiol       Date:  1997-09

3.  RNA-d2: a computer program for editing and display of RNA secondary structures.

Authors:  J Perochon-Dorisse; F Chetouani; S Aurel; N Iscolo; B Michot
Journal:  Comput Appl Biosci       Date:  1995-02

4.  Transforming growth factor-alpha enhances cyclin D1 transcription through the binding of early growth response protein to a cis-regulatory element in the cyclin D1 promoter.

Authors:  Y X Yan; H Nakagawa; M H Lee; A K Rustgi
Journal:  J Biol Chem       Date:  1997-12-26       Impact factor: 5.157

5.  Egr-1 is activated in endothelial cells exposed to fluid shear stress and interacts with a novel shear-stress-response element in the PDGF A-chain promoter.

Authors:  L M Khachigian; K R Anderson; N J Halnon; M A Gimbrone; N Resnick; T Collins
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-10       Impact factor: 8.311

6.  Internalization of oligodeoxynucleotide antisense to type-1 plasminogen activator inhibitor mRNA in endothelial cells: a three-dimensional reconstruction by confocal microscopy.

Authors:  E Wyroba; Z Pawlowska; A Kobylanska; E Pluskota; M Maszewska; W J Stec; C S Cierniewski
Journal:  Biol Cell       Date:  1996       Impact factor: 4.458

7.  Transcription factor Egr-1 regulates glomerular mesangial cell proliferation.

Authors:  G Hofer; C Grimmer; V P Sukhatme; R B Sterzel; H D Rupprecht
Journal:  J Biol Chem       Date:  1996-11-08       Impact factor: 5.157

8.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.

Authors:  R Morishita; G H Gibbons; K E Ellison; M Nakajima; L Zhang; Y Kaneda; T Ogihara; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

9.  Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix.

Authors:  M A Guvakova; L A Yakubov; I Vlodavsky; J L Tonkinson; C A Stein
Journal:  J Biol Chem       Date:  1995-02-10       Impact factor: 5.157

10.  Antisense oligonucleotides to the p65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries.

Authors:  M V Autieri; T L Yue; G Z Ferstein; E Ohlstein
Journal:  Biochem Biophys Res Commun       Date:  1995-08-24       Impact factor: 3.575

View more
  17 in total

Review 1.  Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.

Authors:  L M Khachigian
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 2.  Egr-1 is a major vascular pathogenic transcription factor in atherosclerosis and restenosis.

Authors:  Florian Blaschke; Dennis Bruemmer; Ronald E Law
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 3.  DNAzymes and cardiovascular disease.

Authors:  V L Benson; L M Khachigian; H C Lowe
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

4.  Time course analysis of gene expression identifies multiple genes with differential expression in patients with in-stent restenosis.

Authors:  Santhi K Ganesh; Jungnam Joo; Kimberly Skelding; Laxmi Mehta; Gang Zheng; Kathleen O'Neill; Eric M Billings; Anna Helgadottir; Karl Andersen; Gudmundur Thorgeirsson; Thorarinn Gudnason; Nancy L Geller; Robert D Simari; David R Holmes; William W O'Neill; Elizabeth G Nabel
Journal:  BMC Med Genomics       Date:  2011-02-28       Impact factor: 3.063

Review 5.  Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury.

Authors:  Neeta Adhikari; Nathan Charles; Ute Lehmann; Jennifer L Hall
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

6.  Egr-1 expression during neointimal development in flow-associated pulmonary hypertension.

Authors:  Michael G Dickinson; Beatrijs Bartelds; Grietje Molema; Marinus A Borgdorff; Bibiche Boersma; Janny Takens; Michel Weij; Pieter Wichers; Hannie Sietsma; Rolf M F Berger
Journal:  Am J Pathol       Date:  2011-09-13       Impact factor: 4.307

7.  Net-targeted mutant mice develop a vascular phenotype and up-regulate egr-1.

Authors:  A Ayadi; H Zheng; P Sobieszczuk; G Buchwalter; P Moerman; K Alitalo; B Wasylyk
Journal:  EMBO J       Date:  2001-09-17       Impact factor: 11.598

8.  Transforming growth factor beta1-mediated activation of the smooth muscle alpha-actin gene in human pulmonary myofibroblasts is inhibited by tumor necrosis factor-alpha via mitogen-activated protein kinase kinase 1-dependent induction of the Egr-1 transcriptional repressor.

Authors:  Xiaoying Liu; Robert J Kelm; Arthur R Strauch
Journal:  Mol Biol Cell       Date:  2009-03-04       Impact factor: 4.138

9.  Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells.

Authors:  Brian D Lamon; Barbara D Summers; Antonio M Gotto; David P Hajjar
Journal:  Eur J Pharmacol       Date:  2009-01-14       Impact factor: 4.432

10.  Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1.

Authors:  Ainslie Mitchell; Crispin R Dass; Lun-Quan Sun; Levon M Khachigian
Journal:  Nucleic Acids Res       Date:  2004-06-04       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.